SureTrader SureTrader SureTrader
Home > Boards > US Listed > Biotechs >

RedHill Biopharma Ltd. (RDHL)

RDHL RSS Feed
Add RDHL Price Alert      Hide Sticky   Hide Intro
Moderator: BioSpecialist, noretreat
Search This Board:
Last Post: 1/22/2017 11:15:51 AM - Followers: 52 - Board type: Free - Posts Today: 0





Market Cap: $60 M
Cash: $14.7 M
Burn-rate : $10 per Year

Shares Out: 6.3 M ( Management holds over 2.6 M shares )
Float: 4 M






Presentation September 2013
http://files.shareholder.com/downloads/AMDA-1C0OBF/2736607566x0x690006/36cdf135-d2c9-4ce8-88d4-df998ade2152/RedHill%20Biopharma%20Presentation%20September%202013.pdf




The Company’s current product pipeline includes:

 

RHB-103 - An oral thin film formulation of rizatriptan, for the treatment of acute migraine, with a U.S. NDA filed and accepted for review by the FDA and a PDUFA date of February 3, 2014.Market Size: Worldwide triptan market for the treatment of migraine exceeds $2 billion*



RHB-102 - A once-daily formulation of ondansetron, for the treatment of chemotherapy and radiotherapy-induced nausea and vomiting, planned for U.S. NDA submission during the first quarter of 2014.Market Size: Worldwide market for serotonin (5-HT3) receptor inhibitors is estimated at $900 million**



RHB-101 - A once-daily formulation of carvedilol, for the treatment of congestive heart failure and high blood pressure, planned to be submitted for a U.S. New Drug Application (NDA) and a Marketing Authorization Application (MAA) in Europe during the second half of 2014.Market Size: Worldwide target market of $500 million**



RHB-105 - A combination therapy for Helicobacter pylori infection, planned to commence a phase II/III trial in the third quarter of 2013.Market Size: U.S. market is estimated at approximately $1-1.5 billion*



RHB-104 - A combination therapy for the treatment of Crohn’s disease, with a phase III clinical study underway.Market Size: Worldwide market exceeded $3.5 billion in 2012



RHB-104 - A combination therapy for the treatment of Multiple Sclerosis (MS), with a Phase IIa proof of concept trial currently underway.Market Size: Worldwide market of over $14 billion*



RHB-104 - A combination therapy for the treatment of Rheumatoid Arthritis, with a planned Phase IIa study.Market Size: Worldwide market of over $20 billion*



RHB-106 - An encapsulated formulation for bowel preparation (laxative) ahead of colonoscopy and other GI procedures.Market Size: Worldwide market is estimated at approximately $1.4 billion*

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
RDHL
Current Price
Volume:
Bid Ask Day's Range
SureTrader
RDHL News: Report of Foreign Issuer (6-k) 01/12/2017 06:05:21 AM
RDHL News: RedHill Biopharma Provides 2017 Semi-Annual Business Update 01/12/2017 06:01:15 AM
RDHL News: RedHill Biopharma Provides 2017 Semi-Annual Business Update 01/12/2017 06:01:00 AM
RDHL News: Report of Foreign Issuer (6-k) 01/11/2017 08:01:45 AM
RDHL News: RedHill Biopharma Announces QIDP Fast-Track Designation Granted by FDA to RHB-104 for Nontuberculous Mycobacteria Infections 01/11/2017 08:00:21 AM
PostSubject
#393  Sticky Note Every time I read about the pipeline listed noretreat 10/31/16 09:55:14 AM
#562   A little low compared to others target price, drugmanrx 01/22/17 11:15:51 AM
#561   RedHill Biopharma Ltd – ADR (NASDAQ:RDHL) target price midastouch017 01/22/17 10:17:25 AM
#560   Agree The next good milestone will be "RHB-104 - Crohn`s Amatuer17 01/12/17 12:12:44 PM
#559   Company is poised for a breakout year. Lots noretreat 01/12/17 10:11:00 AM
#558   RedHill Biopharma Provides 2017 Semi-Annual Business Update midastouch017 01/12/17 09:08:01 AM
#557   RDHL reminds me of my 7+ bagger LGND Amatuer17 01/11/17 08:42:17 AM
#556   RedHill Biopharma Announces QIDP Fast-Track Designation Granted by midastouch017 01/11/17 08:18:33 AM
#555   Another great news out today BioSpecialist 01/11/17 08:14:56 AM
#554   330 this afternoon noretreat 01/10/17 03:00:50 PM
#552   Nice presentation at the showcase today. No surprises, noretreat 01/10/17 01:53:47 PM
#551   Agreed. Well run company with a robust tykundegex 01/10/17 10:53:41 AM
#550   I do not like the share price but Amatuer17 01/10/17 09:03:02 AM
#549   RedHill Biopharma Announces First Dosing in RHB-105 Supportive midastouch017 01/10/17 08:31:48 AM
#548   RedHill Biopharma’s RHB-105 Positive Phase III Study Results midastouch017 01/09/17 09:20:44 AM
#547   This is why I prefer the other Israeli scottsmith 01/07/17 09:24:59 AM
#546   Yes - the biggest concern I have for Amatuer17 01/07/17 09:10:00 AM
#545   105 did quite well in the first phase scottsmith 01/07/17 09:02:01 AM
#544   Agree - that is nearest milestone But I am Amatuer17 01/06/17 11:29:28 AM
#543   It's all about 104 in the next 6 scottsmith 01/06/17 11:18:28 AM
#542   Yes - they are spreading thin. However - one Amatuer17 01/06/17 11:16:53 AM
#541   Perhaps they are spreading midastouch017 01/06/17 08:54:28 AM
#540   The amount of news that is coming out Amatuer17 01/06/17 08:51:20 AM
#539   RedHill Biopharma Announces YELIVA® (ABC294640) Abstract Presentation at midastouch017 01/06/17 08:16:36 AM
#538   This is an aggressive, hard working company. Always chef911 01/05/17 10:22:02 AM
#537   RedHill Biopharma Announces New Research Collaboration with Aarhus midastouch017 01/05/17 08:03:05 AM
#536   RedHill Biopharma to Present the Positive Results of midastouch017 01/04/17 08:05:04 AM
#535   should end with "WHEN approved by the FDA." noretreat 01/03/17 10:02:36 AM
#534   This product is one with controversy on pricing. Amatuer17 01/03/17 09:22:51 AM
#533   Great News and Stock is still brutally underpriced .... BioSpecialist 01/03/17 08:20:02 AM
#532   PR is somewhat light on material facts. scottsmith 01/03/17 07:57:01 AM
#531   RedHill Biopharma Announces Exclusive U.S. Co-Promotion Agreement with Amatuer17 01/03/17 07:07:38 AM
#530   Huh? noretreat 01/01/17 08:40:07 PM
#529   Should be a very interesting year for both scottsmith 12/31/16 08:25:27 AM
#528   Agree on low SP but at least you Amatuer17 12/31/16 05:47:04 AM
#527   all the funding/dilution in the world and still TheHound 12/30/16 04:04:00 PM
#525   Once it breaks the MA(50) at $11.56 then BioSpecialist 12/29/16 10:57:30 AM
#524   New Presentation is out BioSpecialist 12/28/16 11:02:10 AM
#523   I will be there...RedHill Biopharma to Present at noretreat 12/28/16 07:22:36 AM
#522   EMC2 Fund Ltd participated in the registered direct toddski 12/27/16 11:15:50 AM
#521   RedHill Biopharma Announces Closing of Concurrent Public Offering midastouch017 12/27/16 10:45:18 AM
#520   Great Analysis by J.Napodano he says stock should BioSpecialist 12/27/16 09:02:19 AM
#519   It is a compelling buy. In between the toddski 12/24/16 10:16:44 AM
#518   If you don't consider RDHL as a compelling tykundegex 12/24/16 09:06:07 AM
#517   Check back in a couple years. We shall noretreat 12/23/16 07:51:44 PM
#516   Now that the public offering is midastouch017 12/23/16 02:51:16 PM
#515   More Infos about this undiscovered Goldmine .... BioSpecialist 12/23/16 02:07:32 PM
#514   RDHL is massive undervalued and heavily oversold should BioSpecialist 12/23/16 10:38:24 AM
#513   test BioSpecialist 12/22/16 01:25:56 PM
#512   test BioSpecialist 12/22/16 01:25:46 PM
#511   test BioSpecialist 12/22/16 01:25:36 PM
PostSubject